Superworth

Aytu Biopharma free cash flow AYTU

Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.

Last 12 months, to Jun 30, 2026
$3.3M
Latest quarter, Q4 FY26
$4.4M
+58% on a year earlier
Fiscal year 2026
$3.3M

Aytu Biopharma's free cash flow was $3.3M over the twelve months to Jun 30, 2026.

In its latest quarter, Q4 FY26, it was $4.4M, up 58% on the same quarter a year before.

Free cash flow over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearFree cash flowChange
FY2026$3.3Mn/a
FY2025−$2.2Mn/a
FY2024n/an/a
FY2021n/an/a
FY2020−$29.7Mn/a
FY2019−$13.9Mn/a
FY2018n/an/a
FY2017−$13.9Mn/a
FY2016−$10.9Mn/a
FY2015n/an/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedFree cash flowOn a year earlierLast 12 months
Q4 FY26$4.4M+58%$3.3M
Q3 FY26−$4.2Mn/a$1.6M
Q2 FY26$3.7M+26%−$698K
Q1 FY26−$618Kn/a−$1.5M
Q4 FY25$2.8Mn/a−$2.2M
Q3 FY25−$6.5Mn/a−$6.1M
Q2 FY25$2.9Mn/a$202K
Q1 FY25−$1.3Mn/an/a
Q4 FY24−$1.1Mn/an/a
Q3 FY24−$254Kn/an/a
Q4 FY21$6.8Mn/an/a
Q4 FY20−$7.8Mn/a−$29.7M

Against its peers

Companies in Drug Manufacturers - General nearest Aytu Biopharma's size, closest first, today.

CompanyFree cash flow yield
AYTUAytu Biopharma15.8%
ATNMActinium Pharmaceuticalsn/m
SPROSpero Therapeuticsn/m
LFVNLifevantage9.1%
Peer median9.1%

Where Aytu Biopharma ranks

What the free cash flow tells you

Cash from operations minus capital spending. The cash the company could hand back or reinvest.

Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.

More on Aytu Biopharma

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.